Trial Profile
Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms RESPONDER
- 03 Aug 2017 New trial record